Peptide · Melanocortin
Promotes eumelanin production; approval is limited to a rare photosensitivity disorder.
Also known as: Melanotan I · MT-1 · MT-I · MT-1 Melanotin Receptor Type 1 · α-MSH analogue · Scenesse
Afamelanotide
Promotes eumelanin production; approval is limited to a rare photosensitivity disorder.
Medicine instructions · named product only
Product or source: Afamelanotide · SCENESSE · EPP
Approved uses exist, but dose, formulation, device and monitoring are product- and indication-specific. A community table cannot replace the prescribing information or a prescription.
SCENESSE label: one 16 mg implant every two months, exclusively for adults with erythropoietic protoporphyria.
Profile evidence level: established.
The implant is inserted by trained medical staff; it is not an injectable community vial.
No individual recommendation.
Repeat administration follows the approved indication and prescribing information, not a tanning cycle.
No individual recommendation.
No. An implant is not dissolved in water.
SCENESSE is a controlled-release implant. It is not reconstituted; unregulated 'Melanotan I' vials or sprays are not the same product.
mg or µg describe the mass of a substance. That is not the same as ml of fluid or U on a syringe. The number is only the amount stated by the identified source.
The interval only describes the time stated between two points. For example, once every 7 days does not mean daily and never justifies catching up or doubling.
A cycle is a stated period that may include breaks. A community cycle proves neither effectiveness nor safety and does not prevent long-term risks.
Reconstitution means mixing powder with a defined volume of fluid. This changes concentration, not the total amount in the vial. On U-100, 100 U equals exactly 1 ml of volume.
Not a guide to misuse
All community figures are shown only to place widely circulated online protocols in context. They are not instructions for self-use, injection, performance enhancement or any other misuse. Approved figures apply only to the exact named product, approved indication and medical supervision.
Mechanism: what is supported and what does not follow
Afamelanotide is classified as “Melanocortin-1 receptor agonist”. Promotes eumelanin production; approval is limited to a rare photosensitivity disorder. This describes the investigated pathway but does not validate a community use, amount, route or combination.
This studies how activating melanocortin receptors affects pigmentation or sexual arousal signals, like a switch controlling different body functions depending on the receptor subtype. Skin pigmentation or physiological arousal markers are measured in studies.
This studies how skin pigment cells respond to signals that darken skin, potentially reducing sensitivity to sunlight, similar to how a photograph darkens with more exposure. Researchers typically measure skin pigment levels and light sensitivity in study participants.
This examines effects on hormone axes influencing libido, cycle, or fertility, similar to a feedback loop connecting several glands. Hormone levels and subjective questionnaires are measured in studies.
These themes describe discussions and vendor claims. They do not prove benefit, safety, product identity or suitable use.
Users compare tanning or skin changes after using melanocortin-related substances, often based on shared photos rather than medical examination. Such posts do not establish reviewed safety, especially for unapproved variants.
Discussion covers which vendors are seen as more trustworthy and how purity test results differ between batches. Such community assessments are based on limited samples and do not replace independent lab testing of each individual batch.
Broader wellbeing impressions such as mood, sleep, and general feeling after using various products are exchanged here, usually without structured tracking. Such general impressions are not a substitute for targeted clinical examination.
Adverse effects and safety risks
Do not self-use / obtain clinical review
Monitoring and laboratory markers
Evidence boundary
Approval covers only the specific photosensitivity disorder.
Clinical evidence
The described biological role is well established, or extensive regulator-reviewed human data exist for clearly defined products and uses. This does not automatically transfer to other products or purposes.
Afamelanotide selectively targets the melanocortin-1 receptor and is approved for a rare disorder, unlike the non-selective, unapproved Melanotan II.
Storage and stability
Troubleshooting and common errors
Regulatory status and WADA
Prescription active ingredient for defined indications in at least one jurisdiction; not offered here.
WADA 2026
The atlas has no explicit WADA flag for this profile. That does not automatically mean every form, route or related class is permitted in sport.
WADA — 2026 Prohibited ListComparison with related substances
Combinations / stacks
Frequently asked questions
No. This page separates approved product information, study protocols and community information. No number or calculator is an individual dosing recommendation.
No. It only converts mass, volume and syringe scale. It cannot check identity, purity, sterility, stability, solvent or medical suitability.
Safety of a combination cannot be inferred from a single-substance profile. Overlapping pathways, medicines and undefined blends can increase risk.
For approved medicines, the current prescribing information and treating professional control. For research substances, conflict shows that no dependable self-use standard exists.
No. Anecdotes can generate questions but do not replace controlled studies, regulatory review, or identity and quality testing.
Sources and evidence hierarchy
Primary sources and official registries take priority. The community reference is labelled separately.
